November 7, 2024 – Talk Bio

Actionable Insights Powered by AI

Sarepta Therapeutics Halts Development of Vesleteplirsen, a Next-Generation Exon-Skipping Therapy for Duchenne Muscular Dystrophy

6 months ago talkbio0Tagged Duchenne, Exon-Skipping Therapy, Feedback - system communication, Landscapes, Muscular Dystrophy, Muscular Dystrophy, Duchenne, SRP-5051, United States Food and Drug Administration, Vesleteplirsen

Sarepta Therapeutics, Vesleteplirsen (SRP-5051), Duchenne Muscular Dystrophy (DMD), Exon-Skipping Therapy, FDA Feedback, Therapeutic Landscape

Genmab Streamlines Operations by Cutting 3 Early-Stage Programs to Boost Phase 3 Pipeline

6 months ago talkbio0Tagged clinical programs, Genmab, Strategic Focus

Genmab, biotech, clinical programs, phase 3 pipeline, strategic focus

Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK

6 months ago talkbio0Tagged Biosciences, Biosimilar Supply, Coherus, COVID19 (disease), Novavax, Supply chain issues, Udenyca, UK, Vaccines

Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK

Nektar Therapeutics Sells Alabama Manufacturing Facility and Reagent Business for $90 Million

6 months ago talkbio0Tagged Divestment, manufacturing site, Nektar Therapeutics

Nektar Therapeutics, manufacturing site, reagent arm, divestment, Ampersand, $90 million

Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition

6 months ago talkbio0Tagged Acquisition, Catalent, competition, Holdings, pharmaceutical market, Revenue Estimates, United States Federal Trade Commission

Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust

Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure

6 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), drug sales, Failure (biologic function), Gilead, Trodelvy, Veklury

Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure

Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development

6 months ago talkbio0Tagged Arcus, Cancer Therapeutic Procedure, Clinical Trials, Combo, domvanalimab, TIGIT gene, zimberelimab

Arcus Biosciences, TIGIT combo, domvanalimab, zimberelimab, cancer treatment, clinical trials

Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents

6 months ago talkbio0Tagged Age related macular degeneration, Agreement, Antibodies, Bispecific, Cancer Therapeutic Procedure, Clinical Trials, Exudative age-related macular degeneration, Neovascular, Royalty, Vascular Endothelial Growth Factor A

Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.

Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook

6 months ago talkbio0Tagged Advice, annual, Biktarvy, earnings, Gilead Sciences, HIV, HIV Prevention, Lenacapavir, Veklury

Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention

Acadia Generates $100 Million from Pediatric Disease Priority Review Voucher Sale

6 months ago talkbio0Tagged Acadia, Drug Industry, Financial Transactions, Pediatric brand name, Priority Review

Acadia Pharmaceuticals, Pediatric Disease Priority Review Voucher, Pharmaceutical Industry, Financial Transactions